Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: Efficacy and tolerance

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 2, 2007, Pages 119-123

  Rocha, Cristina M ^a   Perez, Renata M ^b   Narciso, Janaína L ^a   Ferreira, Adalgisa P ^a   Lemos, Lara B ^a   Medina Pestana, José O ^a   Silva, Antonio Eduardo B ^a   Ferraz, Maria Lucia G ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

Acute hepatitis C; End stage renal disease; Hemodialysis; Hepatitis C; Interferon; Side effects

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEMODIALYSIS; HEPATITIS C; HUMAN; LOW DRUG DOSE; MALE; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33846828712     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000252626.73172.f3     Document Type: Article

References (33)

1. Pol S, Vallet-Pichard A, Fontaine H, Lebray P. HCV infection and hemodialysis. Semin Nephrol 2002; 22:331-339.
2. Halfon P, Khiri H, Feryn JM, Sayada C, Chanas M, Ouzan D. Prospective virological follow-up of hepatitis C infection in a haemodialysis unit. J Viral Hepatitis 1998; 5:115-121.
3. Fabrizi F, de Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther 2005; 21:861-869.
4. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36:3-10.
5. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11:1896-1902.
6. Hanafusa T, Ichikawa Y, Yazawa K, Kishikawa H, Fukunishi T, Kanai T, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66:471-476.
7. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29:257-263.
8. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1):17-24.
9. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998; 13:62-67.
10. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74:512-516.
11. Hoofnagle JH. Therapy for acute hepatitis C. N Engl J Med 2001; 345:1495-1497.
12. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
13. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology 2002; 36:S195-S200.
14. Suleymanlar I, Sezer T, Isitan F, Yakupoglu G, Suleymanlar G. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron 1998; 79:353-354.
15. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepatitis 2001; 8:70-77.
16. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif 2004; 22:344-350.
17. Perez RM, Ferraz ML, Figueiredo MS, Contado D, Koide S, Ferreira AP, et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69:489-494.
18. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329-333.
19. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-256.
20. Rocca P, Bailly F, Chevallier M, Chevallier P, Zoulim F, Trepo C. Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients. Gastroenterol Clin Biol 2003; 27:294-299.
21. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721-1731.
22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
23. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
24. Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 1990; 34:489-490.
25. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection: a pilot study. J Viral Hepatitis 2001; 8:287-292.
26. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36:1831-1834.
27. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
28. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997; 92:61-65.
29. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, Garcia G, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:3225-3229.
30. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J Hepatol 2003; 39:1056-1062.
31. Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, et al. Patterns of hepatitis C viremia in patients receiving hemodialysis. Am J Gastroenterol 1997; 92:73-78.
32. Galan F, Perez-Gracia MT, Lozano A, Benavides B, Fernandez-Ruiz E, Rodriguez-Iglesias MA. A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1211-1214.
33. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, et al. Efficacy and tolerance of interferon in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26:305-310.